This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alkermes Expands Senior Management Team

Alkermes plc (NASDAQ: ALKS) today announced that it has expanded its senior management team by appointing two industry veterans to newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of Clinical Development and Medical Affairs, and Peter Norman has joined the company as Vice President of Government Affairs and Policy.

“We are very pleased to welcome Serge and Pete – two proven leaders whose expertise will contribute to Alkermes’ next stage of growth,” said Richard Pops, Chief Executive Officer of Alkermes. “As our portfolio of new medicines expands, we are responding by strengthening our capabilities in two areas critical for our future: global clinical development and government affairs.”

Dr. Serge Stankovic will be responsible for Alkermes’ Clinical Development and Medical Affairs function, which advances and implements the clinical development programs for the company’s pipeline of drug candidates. He will serve on the senior management team at Alkermes and report to Elliot Ehrich, M.D., Senior Vice President of Research & Development and Chief Medical Officer.

“I am very enthusiastic about leading the clinical development programs during this exciting time when Alkermes is expanding its pipeline,” said Dr. Stankovic. “I look forward not only to making progress with the range of clinical studies that are underway and planned for drug candidates, but also to achieving the ultimate goal of delivering valuable medicines that make a difference for patients.”

Mr. Peter Norman will lead Alkermes’ U.S. Government Affairs and Policy function, ranging from activities at federal and state levels, to interactions with professional and patient organizations. He will serve on the senior management team at Alkermes and report to Kathryn Biberstein, Senior Vice President, Chief Legal Officer and Chief Compliance Officer.

“I am excited to join Alkermes at a time when there are so many emerging opportunities to connect the company’s medicines with policy and advocacy initiatives to impact patients, healthcare systems and the public health,” said Mr. Norman. “Alkermes is poised to advance innovative solutions for chronic central nervous system (CNS) diseases that significantly impact both health systems and society. I also look forward to exploring new public affairs and policy strategies for enhancing adoption of, and access to, the company’s products.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,076.21 +132.40 0.78%
S&P 500 1,979.00 +11.43 0.58%
NASDAQ 4,447.1810 +31.6910 0.72%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs